Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
3 Things to Know About Amazon Ahead of Its Stock Split
10:30am, Wednesday, 27'th Apr 2022 The Motley Fool
Are share gains on the way?
How Gilead is positioning its COVID-19 drug against newer antivirals like Paxlovid
09:32am, Wednesday, 27'th Apr 2022
Gilead Sciences Inc. GILD, -0.31% has steadily expanded the use of Veklury while much of the nation's attention has shifted to the arrival of new antivirals that can be picked up at a pharmacy counter
Gilead Sciences to Present at Upcoming Investor Conferences
06:13pm, Tuesday, 26'th Apr 2022
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences: Bank of America Healthcar
Healthcare ETFs in Focus Ahead of Q1 Earnings
03:15pm, Tuesday, 26'th Apr 2022 Zacks Investment Research
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfo
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Protagonist's Ulcerative Colitis Study Disappoints With Higher Dose Of PN-943
Protagonist Therapeutics
Healthcare ETFs in Focus Ahead of Q1 Earnings
12:47pm, Tuesday, 26'th Apr 2022
The healthcare sector has gained some momentum lately on investors' rush to safety in a volatile stock market. The sector is non-cyclical in nature, which in turn, is providing a cushion to the portfo
Gilead (GILD) to Report Q1 Earnings: Is a Beat in the Cards?
03:49pm, Monday, 25'th Apr 2022 Zacks Investment Research
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) first-quarter 2022 results.
FDA formally approves Gilead's Veklury for young children
02:20pm, Monday, 25'th Apr 2022
The Food and Drug Administration said Monday it expanded the approval of Gilead Sciences Inc.'s GILD, -0.27% Veklury to include pediatric patients between the ages of four weeks and 12 years old. (Inf
Gilead (GILD) to Report Q1 Earnings: Is a Beat in the Cards?
01:32pm, Monday, 25'th Apr 2022
Investors will focus on the HIV franchise's performance and Veklury sales in Gilead's (GILD) first-quarter 2022 results.
Glaxo (GSK) to Report Q1 Earnings: What's in the Cards?
01:02pm, Monday, 25'th Apr 2022 Zacks Investment Research
Glaxo's (GSK) COVID-19 solutions, newer respiratory and HIV drugs are likely to have driven first-quarter sales. The performance of vaccines during Q1 remains to be seen.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
09:50pm, Thursday, 21'st Apr 2022 Zacks Investment Research
Gilead Sciences (GILD) closed the most recent trading day at $63.75, moving +0.24% from the previous trading session.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
07:01pm, Thursday, 21'st Apr 2022 Zacks Investment Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Gilead Sciences (GILD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
04:34pm, Thursday, 21'st Apr 2022
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: SRRA Surges on GSK Buyout, HALO Offers Update & More
05:34pm, Thursday, 14'th Apr 2022 Zacks Investment Research
Acquisition news from GlaxoSmithKline (GSK) and HALO are a few key highlights from the biotech sector during the past week.
2 Unstoppable Green Flags for AbbVie
11:00am, Thursday, 14'th Apr 2022 The Motley Fool
There's a silver lining around an approaching dark cloud.
